Dermatology Times 2024 in Review: Psoriasis

Psoriasis Therapies in 2024 and Beyond

Dermatology Times kicked off the year by highlighting approved psoriasis therapies that shaped the 2024 treatment landscape and providing some exciting updates in the psoriasis management market.

Guselkumab Significantly Clears Scalp Psoriasis in Patients With Skin of Color in Phase 3b VISIBLE

The VISIBLE clinical program will create a longitudinal collection of more than 20,000 clinical images across all skin tones.

Targeted Oral Peptide JNJ-2113 Led to Significant PASI, IGA Responses in Phase 2b Trial for Plaque Psoriasis

Data from the FRONTIER 1 clinical trial were published in the New England Journal of Medicine in February of this year.

First Patient Dosed in Phase 2a Trial of AX-158 for Psoriasis

The investigational oral, small molecule immunomodulator selectively modulates T cell responses and acts as a T cell receptor. It has the capability to be used as monotherapy or in combination with another therapy.

FDA Approves Boehringer Ingelheim's Spesolimab-sbzo For Adults and Children With Generalized Pustular Psoriasis

The expanded approval of Spevigo follows the Chinese National Medical Products Administration’s approval for the injection for the reduction of occurrence of GPP.

Kim Papp, MD, PhD, FRCPC: Exploring the Potential of ESK-001 in Plaque Psoriasis

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.

Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

Loretta Fiorillo, MD, FRCPC, reviews key data points from the phase 3 SPROUT study.

ICYMI: US FDA Recently Approves Stelara Biosimilar Ustekinumab-aekn for Psoriasis, Psoriatic Arthritis

The FDA approved ustekinumab (Stelara) biosimilar ustekinumab-aekn (Selarsdi) to treat moderate to severe plaque psoriasis and active psoriatic arthritis in adults and children aged 6 years and older. This approval marks the second biosimilar approval for the strategic partnership between Alvotech and Teva.

FDA Approves A High-Concentration, Citrate-Free Version of Cyltezo, A Biosimilar to Humira

Cyltezo, available in both high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations, is offered at competitive prices compared to Humira.

Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Ayesha Patrick: Advocacy, Representation, and Hope Via AbbVie's Clearly Me Campaign

Ayesha Patrick, the founder of Sistas With Psoriasis, spoke with Dermatology Times about her involvement in AbbVie's Clearly Me campaign.

Brodalumab Performs in Phase 4 Studies of Moderate to Severe Psoriasis

The results indicated improvement in PASI and sPGA scores as well as improvement in quality of life indicators in adults with moderate to severe psoriasis.

AbbVie Unveils Promising 148-Week VALUE Trial Data for Risankizumab at IFPA Conference

Risankizumab outperformed other biologics in real-world psoriasis treatment, achieving higher PASI 90/100 rates and patient satisfaction.

Arcutis Submits sNDA for Roflumilast Foam to FDA for Scalp and Body Psoriasis

The submission to the FDA is supported by positive results from the pivotal ARRECTOR phase 3 trial (NCT05028582) and a phase 2b study, alongside long-term efficacy and safety data from the roflumilast development program.

Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS

The data suggest promising long-term outcomes and a potential impact on disease progression in axial spondyloarthritis, particularly AS, which was emphasized in late-breaking presentations.

Q&A: Alumis Inc. Initiates Phase 3 Clinical Program for ESK-001 in Plaque Psoriasis

Alumis' Martin Babler shared insights into the program for the TYK2 inhibitor and the company's next steps for its development.

Apremilast Now Available for Pediatric Use in the US

This marks a significant development for young patients with psoriasis as there are currently no other FDA-approved oral medications for the condition.

FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis

With the acceptance, the FDA has established a Prescription Drug User Fee Act target action date of May 22, 2025.

UCB Presents 4-Year Data on Bimekizumab for Plaque Psoriasis

The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.

UCB Announces Head-to-Head Trial Comparing Bimekizumab and Risankizumab

This marks the first head-to-head trial of an IL-17A/F inhibitor against an IL-23 inhibitor in psoriatic arthritis treatment.

FDA Approves 320 mg Bimekizumab Pre-Filled Syringe and Autoinjector

The new delivery systems for bimekizumab-bkzx represent an upgrade over previous 1 mL options, reducing the frequency of injections required.

AI-Powered Innovation: Zasocitinib’s Journey to Precision Inhibition

November's cover feature highlights the revolutionary role of artificial intelligence in the development of zasocitinib for the treatment of psoriasis.

JNJ-2113 Shows Promising Phase 3 Results for Plaque Psoriasis

The company’s phase 3 trials show JNJ-2113 significantly improves skin clearance and tolerability for patients with moderate to severe psoriasis.

Dermatology Times Hosts Inaugural Horizons in Advanced Practice Meeting

The exclusive event brought together physician assistants and nurse practitioners from across the country to review atopic dermatitis and psoriasis patient cases.

Patient-Reported Outcomes and Treatment Switching in Plaque Psoriasis

Researchers found patients reporting greater disease burden and lower HRQoL are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.